利培酮治疗精神分裂症前后6个月的药物经济学评价

Pharmacoeconomic Evaluation of the Remedial Effectiveness of 55 Shizophrenics for 6 Months Before and After the Risperidone

我们对55例精神分裂症住院病人接受利培酮治疗前后各6个月进行自然条件下的观察,记录病人接受利培酮治疗后6个月的某些直接费用和间接费用指标,并与病人接受利培酮前6个月的相应指标作自身对照,结果表明:病人使用利培酮住院治疗时药费比例每人平均上涨51％,但病人住院期间的护理分级有明显好转。这提示:利培酮具有降低直接费用的效果。同时,使用利培酮后,病人缺勤天数和病人家属缺勤天数较使用利培酮前有明显差异。这种差异提示利培酮还具有明显减少精神分裂症病人的间接费用的作用。本文结论支持:使用利培酮后的总费用降低足以抵消药费的上涨,并能提高病人的生活质量。

A retrospective cohort study was conduct to assess the role of risperidone in reducing cost in the patient with schizophrenia. Methods: The direct cost and some indirect costs were compared in 55 schizophrenics for 6 months before and after the risperidone. Results: Increases was observed in the expense of medication but the decreases were noted for patient's behavior in the ward and for the number of day lost from work both in patients and family memebers who care for the patients. Conclusion: The cost - effectiveness analysis suggested increased cost of risperidone may well be offset by reduced expenditures in the utilization of health care resources and the improved of patients' quality of life.